Advertisement

Identification of 8 novel gene variants in primary hyperoxaluria in 21 Chinese children with urinary stones

  • Lei He
  • Guofeng Xu
  • Xiaoliang Fang
  • Houwei Lin
  • Maosheng Xu
  • Yongguo YuEmail author
  • Hongquan GengEmail author
Original Article
  • 72 Downloads

Abstract

Purpose

We analyzed primary hyperoxaluria (PH) genotype and phenotype in Chinese children. Vitamin B6 response in the patients with genetically confirmed PH1 was also studied.

Methods

We, respectively, analyzed 80 children with urinary stones. Sixty-four children were diagnosed with hyperoxaluria. Twenty-one children consented to genetic evaluation (targeted gene panel-based and whole-exome sequencing), and DNA was obtained from the children and both the parents.

Results

PH accounted for 57.1% (12/21) of hyperoxaluria cases. We reported 12 PH cases, including 5 PH1, 1 PH2, and 6 PH3 cases; 2 novel mutations in AGXT and GRHPR each and 4 HOGA1 mutations were identified. The mutations in AGXT and GRHPR were c0.1161C>A and c0.551C>A, and c0.370C>T and c0.864_865delTG, respectively. Four HOGA1 mutations, c0.290G>A, c0.110G>A, c0.554C>T and c0.834_834 + 1delinsTT, were not reported previously. The average urine Ox 24 level in the PH patients was 0.91 mmol/1.73 m2. Moreover, the average urine Ox 24 level in the PH1 patients (1.07 mmol/1.73 m2) was higher than that in the PH2 and PH3 patients (0.73 mmol/1.73 m2 and 0.71 mmol/1.73 m2, respectively). The eGFR of the PH1 patients (76.86 mL/min) was lower than that of the PH2 and PH3 patients (132 mL/min and 136 mL/min, respectively).

Conclusions

PH incidence was higher than the reported PH incidence in children with urinary stones. Hence, we suggested that genetic examination was necessary for all the children with hyperoxaluria. These novel mutations broaden the range of known gene mutations in PH.

Keywords

AGXT GRHPR HOGA1 Primary hyperoxaluria 

Abbreviations

PH

Primary hyperoxaluria

ESRD

End-stage renal disease

AGT

Alanine–glyoxylate aminotransferase

HOGA

4-Hydroxy-2-oxoglutarate aldolase

eGFR

Estimated glomerular filtration rate

UOx

Urinary oxalate

Notes

Author contributions

LH: data collection or management, data analysis, and manuscript writing. GX: data collection or management and data analysis. XF: data collection or management. HL: data collection or management. MX: data analysis. YY: protocol development. HG: protocol development and manuscript editing

Funding

This study was funded by the National Natural Science Foundation of China (Grant no. 81770702).

Compliance with ethical standards

Conflict of interest

All authors declare no conflicts of interest, real or perceived, financial or nonfinancial.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N (1995) Epidemiology of primary hyperoxaluria type 1. Societe de Nephrologie and the Societe de Nephrologie Pediatrique. Nephrol Dial Transplant 10(Suppl 8):3–7CrossRefGoogle Scholar
  2. 2.
    van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA (2003) Primary hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol Dial Transplant 18(2):273–279CrossRefGoogle Scholar
  3. 3.
    Harambat J, van Stralen KJ, Espinosa L, Groothoff JW, Hulton SA, Cerkauskiene R, Schaefer F, Verrina E, Jager KJ, Cochat P, European Society for Pediatric Nephrology/European Renal Association-European D, Transplant Association R (2012) Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin J Am Soc Nephrol CJASN 7(3):458–465.  https://doi.org/10.2215/CJN.07430711 CrossRefPubMedGoogle Scholar
  4. 4.
    Williams EL, Acquaviva C, Amoroso A, Chevalier F, Coulter-Mackie M, Monico CG, Giachino D, Owen T, Robbiano A, Salido E, Waterham H, Rumsby G (2009) Primary hyperoxaluria type 1: update and additional mutation analysis of the AGXT gene. Hum Mutat 30(6):910–917.  https://doi.org/10.1002/humu.21021 CrossRefPubMedGoogle Scholar
  5. 5.
    Hoppe B (2012) An update on primary hyperoxaluria. Nat Rev Nephrol 8(8):467–475.  https://doi.org/10.1038/nrneph.2012.113 CrossRefPubMedGoogle Scholar
  6. 6.
    Cregeen DP, Williams EL, Hulton S, Rumsby G (2003) Molecular analysis of the glyoxylate reductase (GRHPR) gene and description of mutations underlying primary hyperoxaluria type 2. Hum Mutat 22(6):497.  https://doi.org/10.1002/humu.9200 CrossRefPubMedGoogle Scholar
  7. 7.
    Monico CG, Rossetti S, Belostotsky R, Cogal AG, Herges RM, Seide BM, Olson JB, Bergstrahl EJ, Williams HJ, Haley WE, Frishberg Y, Milliner DS (2011) Primary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasis. Clin J Am Soc Nephrol CJASN 6(9):2289–2295.  https://doi.org/10.2215/CJN.02760311 CrossRefPubMedGoogle Scholar
  8. 8.
    Hopp K, Cogal AG, Bergstralh EJ, Seide BM, Olson JB, Meek AM, Lieske JC, Milliner DS, Harris PC, Rare Kidney Stone C (2015) Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J Am Soc Nephrol 26(10):2559–2570.  https://doi.org/10.1681/ASN.2014070698 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Ruhayel Y, Tepeler A, Dabestani S, MacLennan S, Petrik A, Sarica K, Seitz C, Skolarikos A, Straub M, Turk C, Yuan Y, Knoll T (2017) Tract sizes in miniaturized percutaneous nephrolithotomy: a systematic review from the European Association of Urology Urolithiasis Guidelines Panel. Eur Urol 72(2):220–235.  https://doi.org/10.1016/j.eururo.2017.01.046 CrossRefPubMedGoogle Scholar
  10. 10.
    Williams EL, Bagg EA, Mueller M, Vandrovcova J, Aitman TJ, Rumsby G (2015) Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing. Mol Genet Genom Med 3(1):69–78.  https://doi.org/10.1002/mgg3.118 CrossRefGoogle Scholar
  11. 11.
    Coulter-Mackie MB, Applegarth D, Toone JR, Henderson H (2004) The major allele of the alanine:glyoxylate aminotransferase gene: seven novel mutations causing primary hyperoxaluria type 1. Mol Genet Metab 82(1):64–68.  https://doi.org/10.1016/j.ymgme.2004.02.001 CrossRefPubMedGoogle Scholar
  12. 12.
    Belostotsky R, Seboun E, Idelson GH, Milliner DS, Becker-Cohen R, Rinat C, Monico CG, Feinstein S, Ben-Shalom E, Magen D, Weissman I, Charon C, Frishberg Y (2010) Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet 87(3):392–399.  https://doi.org/10.1016/j.ajhg.2010.07.023 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Allard L, Cochat P, Leclerc AL, Cachat F, Fichtner C, De Souza VC, Garcia CD, Camoin-Schweitzer MC, Macher MA, Acquaviva-Bourdain C, Bacchetta J (2015) Renal function can be impaired in children with primary hyperoxaluria type 3. Pediatr Nephrol 30(10):1807–1813.  https://doi.org/10.1007/s00467-015-3090-x CrossRefPubMedGoogle Scholar
  14. 14.
    Williams EL, Bockenhauer D, van’t Hoff WG, Johri N, Laing C, Sinha MD, Unwin R, Viljoen A, Rumsby G (2012) The enzyme 4-hydroxy-2-oxoglutarate aldolase is deficient in primary hyperoxaluria type 3. Nephrol Dial Transplant 27(8):3191–3195.  https://doi.org/10.1093/ndt/gfs039 CrossRefPubMedGoogle Scholar
  15. 15.
    Zhao F, Bergstralh EJ, Mehta RA, Vaughan LE, Olson JB, Seide BM, Meek AM, Cogal AG, Lieske JC, Milliner DS, Investigators of Rare Kidney Stone C (2016) Predictors of incident ESRD among patients with primary hyperoxaluria presenting prior to kidney failure. Clin J Am Soc Nephrol 11(1):119–126.  https://doi.org/10.2215/CJN.02810315 CrossRefPubMedGoogle Scholar
  16. 16.
    Rumsby G, Cochat P (2013) Primary hyperoxaluria. N Engl J Med 369(22):2163.  https://doi.org/10.1056/NEJMc1311606 CrossRefPubMedGoogle Scholar
  17. 17.
    Cochat P, Hulton SA, Acquaviva C, Danpure CJ, Daudon M, De Marchi M, Fargue S, Groothoff J, Harambat J, Hoppe B, Jamieson NV, Kemper MJ, Mandrile G, Marangella M, Picca S, Rumsby G, Salido E, Straub M, van Woerden CS, OxalEurope (2012) Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant 27(5):1729–1736.  https://doi.org/10.1093/ndt/gfs078 CrossRefPubMedGoogle Scholar
  18. 18.
    Hoyer-Kuhn H, Kohbrok S, Volland R, Franklin J, Hero B, Beck BB, Hoppe B (2014) Vitamin B6 in primary hyperoxaluria I: first prospective trial after 40 years of practice. Clin J Am Soc Nephrol CJASN 9(3):468–477.  https://doi.org/10.2215/CJN.06820613 CrossRefPubMedGoogle Scholar
  19. 19.
    M'Dimegh S, Omezzine A, M'Barek I, Moussa A, Mabrouk S, Kaarout H, Souche G, Chemli J, Aloui S, Aquaviva-Bourdain C, Achour A, Abroug S, Bouslama A (2016) Mutational analysis of Agxt in tunisian population with primary hyperoxaluria type 1. Ann Hum Genet.  https://doi.org/10.1111/ahg.12178 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pediatric UrologyXin Hua Hospital Affiliated To Shanghai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations